Provider Briefing: Cefuroxime Supply in 2026

Cefuroxime — a second-generation cephalosporin and a workhorse antibiotic for community-acquired infections — has experienced intermittent supply disruptions in recent years. As a prescriber, understanding the current landscape helps you make better prescribing decisions and set realistic expectations with patients.

This briefing covers the shortage timeline, prescribing implications, availability picture, cost considerations, and tools to help your patients access Cefuroxime in 2026.

Shortage Timeline

Cefuroxime supply issues are not new. Here's how we got here:

• 2017-2018: Teligent discontinued all Zinacef (Cefuroxime Sodium) injection presentations in February 2018, removing a significant source of IV supply.
• 2019-2022: Sagent Pharmaceuticals reported recurring shortages of Cefuroxime injection due to manufacturing delays and increased demand. Hikma also reported intermittent supply constraints.
• 2023-2024: The ASHP Drug Shortages list continued to list Cefuroxime Sodium injection intermittently. Oral Cefuroxime Axetil remained generally available nationwide but experienced localized outages during respiratory infection season.
• 2025-2026: The injectable form remains on the ASHP shortage list intermittently. Oral formulations (250 mg and 500 mg tablets, oral suspension) are not in a formal national shortage but are subject to local availability issues, particularly during October through March.

Prescribing Implications

The supply landscape has several practical consequences for clinical decision-making:

Oral Step-Down Pressure

When IV Cefuroxime is unavailable, inpatient teams may transition patients to oral therapy earlier than planned. This is generally safe for appropriate patients but increases demand for oral Cefuroxime Axetil and may contribute to pharmacy-level stockouts.

Formulary Considerations

Some hospital formularies have added Cefuroxime alternatives (Ceftriaxone for IV, Cefdinir or Cefpodoxime for oral) as primary options when Cefuroxime is unavailable. If your institution hasn't updated its formulary guidance, consider working with your pharmacy team to establish therapeutic interchange protocols.

Patient Communication

Patients who receive a prescription for Cefuroxime and then can't fill it may delay treatment, self-treat, or lose confidence in the healthcare system. Proactive communication matters — let patients know that if Cefuroxime is unavailable, your office can quickly prescribe an alternative.

Current Availability Picture

As of early 2026:

• Cefuroxime Sodium Injection (750 mg, 1.5 g): Intermittent shortage. Check ASHP for current manufacturer status. Hikma and B. Braun are among suppliers.
• Cefuroxime Axetil 250 mg tablets: Generally available. Multiple generic manufacturers.
• Cefuroxime Axetil 500 mg tablets: Generally available with occasional localized stockouts.
• Cefuroxime Axetil oral suspension (125 mg/5 mL, 250 mg/5 mL): Availability varies. Some pharmacies may need to special-order suspension formulations.

Cost and Access Considerations

Cefuroxime Axetil is a Tier 1 or Tier 2 generic on most insurance formularies. Patients with insurance typically pay $0 to $15 in copays. For uninsured or underinsured patients:

• Discount coupons: GoodRx, SingleCare, and RxSaver bring the cost of 14 tablets (500 mg) down to $13 to $18.
• Retail cash price: Without coupons, $40 to $65 for a typical course.
• No manufacturer savings program: Ceftin is no longer actively marketed, and no copay card exists for generic Cefuroxime.
• Patient assistance: NeedyMeds and RxAssist maintain databases of assistance programs that may cover antibiotic costs for qualifying patients.

For detailed cost-saving strategies to share with patients, see how to help patients save money on Cefuroxime.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder allows you and your staff to check real-time Cefuroxime stock at pharmacies near your patients. This can be integrated into your prescribing workflow — before sending a prescription, verify that a nearby pharmacy has it available.

ASHP Drug Shortages

The ASHP Drug Shortages Resource Center provides the most up-to-date information on Cefuroxime injection availability, including manufacturer-specific updates and estimated resupply dates.

Therapeutic Alternatives Reference

When Cefuroxime is unavailable, consider these evidence-based alternatives:

• For sinusitis/otitis media: Amoxicillin-Clavulanate, Cefdinir, or Cefpodoxime
• For community-acquired pneumonia: Amoxicillin-Clavulanate or a respiratory fluoroquinolone (if indicated)
• For UTIs: Cephalexin, Cefpodoxime, or Nitrofurantoin
• For early Lyme disease: Doxycycline (first line), Amoxicillin (second line)
• For skin/soft tissue infections: Cephalexin, Dicloxacillin, or Clindamycin

For a patient-facing overview of alternatives, you can direct patients to alternatives to Cefuroxime.

Looking Ahead

The broader antibiotic supply chain remains fragile. Generic antibiotics operate on thin margins, and consolidation among manufacturers means fewer backup suppliers when disruptions occur. Advocacy groups continue to push for policy changes — including reimbursement reform and manufacturing incentives — to stabilize the supply of essential generic antibiotics.

In the meantime, staying informed and maintaining flexible prescribing practices is the best defense against supply disruptions.

Final Thoughts

Cefuroxime remains a valuable antibiotic for community-acquired infections, and the oral form is generally findable with some effort. The injectable form continues to face intermittent shortages that may persist through 2026.

Equip your practice with real-time stock-checking tools like Medfinder for Providers, establish therapeutic interchange protocols, and communicate proactively with patients about potential availability issues. For a comprehensive guide on supporting your patients through this process, see how to help your patients find Cefuroxime in stock.